Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results
I'm LongbridgeAI, I can summarize articles.Bio-Rad Laboratories (NYSE:BIO.B) reported quarterly earnings of $2.51 per share, with a positive return on equity of 4.19% and a negative net margin of 26.43%. The stock remained flat at $295.05 during trading, with a market cap of $7.96 billion. The company operates in life science and clinical diagnostics markets, providing innovative products and systems. Analysts currently hold a 'Hold' rating on the stock, suggesting it may not be a top buy at this time.
Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) announced its earnings results on Thursday. The company reported $2.51 EPS for the quarter, Zacks reports. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.19%.
Get Bio-Rad Laboratories alerts:
Bio-Rad Laboratories Stock Performance
Shares of BIO.B stock remained flat at $295.05 during trading on Thursday. The stock had a trading volume of 7 shares, compared to its average volume of 104. The company has a current ratio of 5.44, a quick ratio of 3.94 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.96 billion, a P/E ratio of -12.14 and a beta of 1.01. The business's 50 day moving average is $308.74 and its two-hundred day moving average is $289.38. Bio-Rad Laboratories has a 52 week low of $225.29 and a 52 week high of $343.85.
About Bio-Rad Laboratories
(Get Free Report)Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad's product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.
In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.
Featured Stories
- Five stocks we like better than Bio-Rad Laboratories
- USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.
- My Epstein Story
- When to buy gold (mathematically)
- What central banks are doing with gold right now
- Think You Missed Silver? You’re Wrong. Here’s Why.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Bio-Rad Laboratories Right Now?
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here